Skip to main content
. Author manuscript; available in PMC: 2008 Sep 1.
Published in final edited form as: Biochem Pharmacol. 2007 Jun 14;74(5):752–757. doi: 10.1016/j.bcp.2007.06.005

Fig. 2. Wound closure time course for rats receiving IntraSite™® gel infused with the selective, nonpeptide NK-1 or NK-2 receptor antagonist, RP 67580 or GR 159897.

Fig. 2

Data are presented as area (mm2) mean ± SEM and were determined by analysis of digital images. (A) Rats received applications of IntraSite™® gel (150 μl) to the wound twice daily through wound day 14. IntraSite™® gel infused with 1 mM RP 67580 (n=8) significantly delayed wound closure compared to gel-only controls (n=8). Gel + RP 67580 treated rats had significantly larger wound areas when compared to gel-only controls on wound days 2, 3, 4, 5, 6, and 8. (B) IntraSite™® gel (150 μl) was applied topically to the wound twice daily through wound day 13. Treatment with 3 mM GR 159897 (n=6) significantly delayed wound closure compared to gel-only controls (n=6) with significant increases in wound area compared to control on days 1–8 post-wounding (*p ≤ 0.05; ANOVA, Tukey’s post-hoc test).